The number of tumor-infiltrating CD45+ and CD8+ cells increased following treatment with the neoAg-mRNA-LNP vaccine and/or anti-PD-1 antibody, whereas no such increase was observed with the neoAg-DC vaccine (Fig. 3c and d). This evidence concerns the gene PTPRC and neoplasm.